Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 3Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Lymphoma, B-Cell 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 9Oxaliplatin 6Cisplatin 6Capecitabine 6durvalumab 4apatinib 4S 1 (combination) 4Irinotecan 4Immune Checkpoint Inhibitors 4surufatinib 3Injections 3Drug Therapy 3pembrolizumab 2lenvatinib 2camrelizumab 2Taxes 2Leucovorin 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1taxane 1spartalizumab 1sintilimab 1regorafenib 1manganese chloride 1irinotecan sucrosofate 1gimeracil 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Biliary Tract Neoplasms × gemcitabine-oxaliplatin regimen × Clear all
NCT06320301 2024-03-20

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
43 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡